NRG Oncology/NSABP B-51/RTOG1304 Primary Outcomes – Terry Mamounas, MD [SABCS 2023] Breast 2 Mins Read23 By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist Terry Mamounas, MD, the NSABP…
Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD Gastrointestinal 13 Mins Read1 Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD By…
